Pertuzumab Retreatment Improves OS in HER2-Positive Locally Advanced or Metastatic Breast Cancer
Yutaka Yamamoto, MD, Kumamoto University Hospital, Kunamoto, Japan, discusses overall survival (OS) results from the phase 3 PRECIOUS trial that evaluated pertuzumab retreatment in patients with HER2-positive locally advanced or metastatic breast cancer.
The trial demonstrated that retreatment with pertuzumab in combination with trastuzumab and chemotherapy lead to a significant improvement in OS compared to treatment with trastuzumab and chemotherapy alone.
Dr Yamamoto presented these findings at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Source:
Yamamoto Y, Iwata H, Takahashi M, et al. Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS). Presented at 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract 1015